U.S. Markets closed

DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model

By Brian Marckx, CFA

NASDAQ:DRRX | NASDAQ:PCRX

READ THE FULL DRRX RESEARCH REPORT

POSIMIR CRL Response Made. Favorable Decision Would Likely Mean Significant Upside to Our Model
This morning, Durect (DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR is the company’s investigational post-operative pain relief depot that utilizes the company’s patented SABER technology and is intended to deliver bupivacaine to provide three days of pain relief after surgery.

As a reminder DRRX submitted an NDA ((via 505(b)(2) pathway)) to FDA for POSIMIR in April 2013. FDA responded in February 2014 with a Complete Response Letter. Following interaction with the agency, Durect conducted and completed a Phase 3 clinical trial of POSIMIR (PERSIST trial). As reported in October 2017, while results favored POSIMIR, the trial failed to meet its primary endpoint of a statistically significant reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCI. To-date Durect has completed a total of 16 clinical studies with POSIMIR.

DRRX recently engaged Dr. Lee S. Simon, a physician and previous (2001 – 2003) Director of FDA’s Analgesic, Anti-inflammatory and Ophthalmologic Drug Products division, to evaluate potential next-steps with POSIMIR. The decision to submit a response to the CRL was based on Dr. Simon’s review of the PERSIST data – which presumably means that he believes the package that they compiled and submitted was sufficient (based on his insight and experience with FDA’s Analgesic division, particularly in terms of what they need as support) to warrant eventual approval of the POSIMIR NDA. Per Dr. Simon’s comment in this morning’s press release, "We believe that the submitted response to the CRL includes multiple positive adequate and well controlled trials and addresses the issues raised in the FDA's Complete Response Letter."

Importantly, it is our understanding that approval largely hinges on demonstration of sufficient safety and that failure to meet the efficacy endpoint in PERSIST may not be particularly relevant. Further, DRRX’s CRL response includes substantive additional data that supports safety of the drug. FDA’s response is anticipated within six months – which means we may not hear back until sometime near year-end.



As we had removed POSIMIR from our model, a favorable response from FDA would likely provide upside to our estimates. The market for POSIMIR could be substantial and, as such, potential revisions to our model could be as well. As such, we will be eagerly awaiting word from FDA.


View Exhibit I

Similar to POSIMIR, bupivacaine is the active ingredient in Pacira Biosciences’ Exparel, which is also indicated for postsurgical pain relief. Exparel (bupivacaine liposome injectable suspension) generated $331M in sales in 2018 (effectively all of which was from the U.S.) which analysts forecast will grow at a CAGR of almost 11% to $615M by the year 2024. Exparel accounts for 100% of the revenue of Pacira Biosciences’ (PCRX), which currently trades at a market capitalization of $1.8 billion.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.

  • Oil Price Fundamental Daily Forecast –	Slight Rise Indicates Traders Downplaying Recession Concerns
    Business
    FX Empire

    Oil Price Fundamental Daily Forecast – Slight Rise Indicates Traders Downplaying Recession Concerns

    U.S. West Texas Intermediate and international-benchmark Brent crude oil futures are trading better on Friday after gapping yesterday's close. At 08:09 GMT, October WTI crude oil is trading $55.15, up $0.73 or +1.38% and December Brent crude oil is at $57.90, up $0.56 or +0.98%. On Thursday, the U.S. reported that retail sales rose 0.7% in July as consumers bought a range of goods even as they cut back on motor vehicle purchases, according to data that came a day after the 2-year/20-year U.S. Treasury yield inverted for the first time since June 2007 prompting a sell-off in stocks and crude oil.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of CAR.UN.TO earnings conference call or presentation 14-Aug-19 2:00pm GMT

    Q2 2019 Canadian Apartment Properties Real Estate Investment Trust Earnings Call

  • A gun law case before the US Supreme Court has Americans up in arms
    Finance
    Quartz

    A gun law case before the US Supreme Court has Americans up in arms

    The US Supreme Court will soon consider the right to bear arms, something it hasn't done for nearly a decade. The case in question has pitted New York City against the New York State Pistol and Rifle Association over a law on transporting guns. The twist here is that New York City, and its many legal allies, say the case is actually moot.

  • Mark Cuban explains how to make a 16% guaranteed return
    Business
    MarketWatch

    Mark Cuban explains how to make a 16% guaranteed return

    As Mark Cuban, the “Shark Tank” star, billionaire entrepreneur, and NBA franchise owner explains, just pay off your debts. The personal finance site NerdWallet put our revolving credit card balance at $420.22 billion in late 2018. The revolving number is just the credit card debt we carry from month to month.

  • Senior rip-offs are soaring—and you won’t believe who the crooks are
    News
    MarketWatch

    Senior rip-offs are soaring—and you won’t believe who the crooks are

    For financial scammers, that means 10,000 potential new victims every 24 hours. While anyone, anywhere, at anytime can be a victim of a financial scam—and below are some of the most common ones—seniors are particularly at risk. “Older Americans are more vulnerable for many reasons,” says Joe Snyder of the National Adult Protective Services Association (NAPSA), a Washington, D.C.-based nonprofit that works with the financial industry, seniors groups and others to reduce rip-offs.

  • Is SEI Investments a Good Long-Term Buy?
    Business
    Motley Fool

    Is SEI Investments a Good Long-Term Buy?

    SEI Investments (NASDAQ: SEIC) is an odd duckling in that it is a financial software provider but is also an investment management shop. Most people have never heard of the company, but the $8-billion-market-cap stock is a household name in investment management circles. The company has steadily grown its revenue and earnings while delivering strong returns for its shareholders.

  • GE Rebounds as Wall Street Pushes Back Against Allegations
    Business
    Bloomberg

    GE Rebounds as Wall Street Pushes Back Against Allegations

    William Blair analyst Nicholas Heymann questioned whether the whistleblower report is “the last Molotov cocktail” and said he does not believe GE's financial statements purposely misrepresented the company's financial condition and potential liabilities. Harry Markopolos, who was involved in exposing the frauds of investment manager Bernie Madoff, said in a report on Thursday that GE would need to raise its insurance reserves immediately by $18.5 billion in cash -- plus an additional non-cash charge of $10.5 billion when new accounting rules take effect. Some of the allegations made in the report were already known and others were “known unknowns,” the analyst said, adding that the Baker Hughes write-off was already expected.

  • Nvidia beats Q2 earnings
    Business
    Yahoo Finance Video

    Nvidia beats Q2 earnings

    Semiconductor shares have had a volatile year. Today they're on the rise, led by Nvidia, after the graphics chipmaker reported earnings that beat estimates. Bloomberg Intelligence Senior Technology Analyst, Anand Srinivasan, joins Yahoo Finance's Adam Shapiro and Julie Hyman to discuss.

  • Is It Time To Consider Buying Micron Technology, Inc. (NASDAQ:MU)?
    Business
    Simply Wall St.

    Is It Time To Consider Buying Micron Technology, Inc. (NASDAQ:MU)?

    Micron Technology, Inc. (NASDAQ:MU) saw a significant share price rise of over 20% in the past couple of months on the NASDAQGS. Today I will analyse the most recent data on Micron Technology's outlook and valuation to see if the opportunity still exists. What is Micron Technology worth?

  • Investors Are Missing the Boat on GoPro
    Business
    Motley Fool

    Investors Are Missing the Boat on GoPro

    There are a number of reasons GoPro's stock dropped, but the biggest two were second-quarter results falling short of expectations and uncertainty around new products. Management is bullish that the back half of the year will be big -- and maybe investors should be, too. Excitement over an unknown GoPro increased revenue growth guidance by 200 basis points during its earnings conference call to a range of 9% to 12%.

  • Here's Why Accuray Stock Is Nosediving Today
    Business
    Motley Fool

    Here's Why Accuray Stock Is Nosediving Today

    Shares of Accuray (NASDAQ: ARAY) were nosediving 11.3% as of 11:33 a.m. EDT on Friday. The big drop came after the radiation oncology systems maker reported disappointing fiscal 2019 fourth-quarter results after the market closed on Thursday. Accuray also provided revenue guidance for full-year 2020 that was lower than anticipated.

  • CenturyLink Cobbles Together a Decent Second Quarter
    Business
    Motley Fool

    CenturyLink Cobbles Together a Decent Second Quarter

    Yet there's hope, as second-quarter revenue notched only a small drop from the previous quarter and the company is getting ready to make some infrastructure investments that could pay off down the road. The stock certainly isn't for those who don't like risk, but some reasons for cautious optimism might be emerging. The top and bottom lines are moving in opposite directions Revenue in the second quarter of 2019 fell 5.5% year over year as sales across all of CenturyLink's segments declined save for in the international and global accounts segment, where revenue was flat.

  • GE shares rebound after worst day in 11 years
    Business
    Yahoo Finance Video

    GE shares rebound after worst day in 11 years

    GE shares rebounded on Friday after CEO Larry Culp made a big bet on the company in the wake of fraud accusations made by Madoff whistleblower Harry Markopolos. Yahoo Finance's Myles Udland and Brian Sozzi discuss.

  • Where the Stock Market Could Be Headed Soon
    Business
    Market Realist

    Where the Stock Market Could Be Headed Soon

    Currently, the S&P 500's dividend yield is higher than the ten-year Treasury yield, making the stock market more attractive to yield-hungry investors, despite higher valuation multiples. July's retail numbers came in yesterday. Numbers suggest consumer sentiment is high despite gloomy expectations.

  • 4 Industry Leaders With Ultra-High Dividends
    Business
    Motley Fool

    4 Industry Leaders With Ultra-High Dividends

    With long-term bond yields at historically low levels, conservative investors may be looking to high-dividend stocks in order to get the returns they seek. For those looking for high dividends in a low-interest world, here are four market leaders that not only are household names but also sport dividend yields north of 4% and look to be safe bets to make good on those payments long term. AT&T (NYSE: T) is currently the second-largest U.S. mobile telecom service provider next to rival Verizon. Both AT&T and Verizon have large recurring subscriber bases and are currently investing heavily in the next-generation wireless communications: 5G.

  • Aurora Cannabis’s Target Price and Valuation
    Business
    Market Realist

    Aurora Cannabis’s Target Price and Valuation

    As of yesterday, Aurora Cannabis (ACB) stock was trading at 7.63 Canadian dollars. Despite the company providing higher-than-expected guidance for fiscal 2019's fourth quarter this year, its stock has fallen 25.6% this month. Why Aurora's stock price fell

  • These 16 money wasters are why so many Americans can’t save for retirement
    News
    MarketWatch

    These 16 money wasters are why so many Americans can’t save for retirement

    From the lofty perch of old age, and after a lifetime of thrift, I declare that I am qualified to comment on how not to waste money. We've all heard the reports: Most Americans live paycheck to paycheck, a large number can't come up with $400 for an emergency, and there's no money to save for retirement and other goals. Most of that data comes from surveys where people are, in effect, saying they don't have enough income.

  • Is Franco-Nevada (TSE:FNV) A Risky Investment?
    Business
    Simply Wall St.

    Is Franco-Nevada (TSE:FNV) A Risky Investment?

    Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. What Is Franco-Nevada's Net Debt? You can click the graphic below for the historical numbers, but it shows that as of June 2019 Franco-Nevada had US$432.2m of debt, an increase on none, over one year.

  • I built a nest egg of $1 million and I’m only 46 — so why do I still spend my waking hours worrying?
    Business
    MarketWatch

    I built a nest egg of $1 million and I’m only 46 — so why do I still spend my waking hours worrying?

    We have over $1 million in investments for ourselves, an additional $50,000 in investments for our two girls to be used for college. We have made investing mistakes, but we have learned from them. All told, we currently have over $1 million in investments for ourselves, an additional $50,000 in investments (529s and a Scottrade custodial account) for our two girls to be used for college, with our only debt being the final few years of our mortgage.

  • Business
    Reuters

    Revlon to explore options, says largest shareholder

    MacAndrews and Forbes, the holding company through which billionaire Ronald Perelman owns about 87% stake in Revlon, disclosed in an SEC filing that an external financial adviser has been retained to help in the efforts. Bloomberg reported on Thursday that Revlon had tapped Goldman Sachs Group Inc, citing sources. Perelman in 2016 too had urged the struggling cosmetics company to explore strategic alternatives as it battled with changing consumer preferences and intense competition from bigger rivals Estee Lauder and L'Oreal SA.

  • This Oil Stock Continues to Prove It's a Cash Flow-Gushing Machine
    Business
    Motley Fool

    This Oil Stock Continues to Prove It's a Cash Flow-Gushing Machine

    The cash continues to flow Wallette pointed out on the call that "we generated $3.4 billion of cash from operations" during the second quarter. That was easily enough to cover the company's capital expenses, which totaled $1.7 billion in the quarter. As a result, the company produced $1.7 billion of free cash flow during the quarter, pushing its year-to-date total to $3 billion.

  • 10 Best Stocks to Buy and Hold Forever
    Business
    InvestorPlace

    10 Best Stocks to Buy and Hold Forever

    In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place. Conversely, the fact that Warren Buffett's favorite holding period is “forever” and how he's got a track record most investors would envy is just as telling. With that as the backdrop, here's a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves.

  • 3 High-Growth Stocks That Are Just Getting Started
    Business
    Motley Fool

    3 High-Growth Stocks That Are Just Getting Started

    Powering the rise of solar energy Maxx Chatsko (Enphase Energy): Sure, shares of Enphase Energy have soared 580% since the beginning of the year, but first-half 2019 operating results suggest there's plenty of room to run. The solar hardware provider reported 60% year-over-year revenue growth and a nearly $28 million increase in operating income in that span. The most recent quarterly results actually exceeded management's long-term targets for gross profits, operating expenses, and operating income, but CEO Badri Kothandaraman said he's going to wait a few more quarters before setting new operating targets.

  • The retirement crisis is bad for everyone — especially these people
    Business
    MarketWatch

    The retirement crisis is bad for everyone — especially these people

    The country is facing a retirement crisis, but some Americans are worse off than others. Workers in the top 20% of earnings distributions have half of all retirement wealth in both 1992 and 2010, compared with the bottom group, which saw its share fall from 3% to 1% between those years, a recent analysis at The New School's Schwartz Center for Economic Policy Analysis (SCEPA) found. The share of workers in the bottom fifth of the earnings distribution with no retirement savings jumped from 45% to 51% in those 18 years.

  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Business
    Motley Fool

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    There's a balance in the dividend space between high yields and dividend sustainability. In the end, it's generally more important to find stocks that can keep paying -- and hopefully increasing -- their dividends than to stretch for high yields that are ephemeral because they are backed by dividends that are likely to get cut. If you want to add a few good dividend names to your portfolio, these three Motley Fool contributors think you'll want to look at biotech Gilead Sciences (NASDAQ: GILD), telecom giant Verizon (NYSE: VZ), and consumer products specialist Procter & Gamble (NYSE: PG).